A. Altavilla, Activity of Ethics Committees in Europe on issues related to clinical trials in paediatrics: Results of a Survey, Pharmaceuticals Policy and Law, vol.11, pp.79-87, 2009.

N. André, P. Leblond, and A. Verschuur, Spécificités pharmacologiques en oncologie pédiatrique, Bulletin du Cancer, vol.97, 2010.

. Aulois-griot, La mise sur le march?? des m??dicaments ?? usage p??diatrique dans l???Union europ??enne et en France??: entre incitations et obligations pour l???industrie pharmaceutique, M??decine & Droit, vol.2008, issue.91, 2008.
DOI : 10.1016/j.meddro.2008.07.001

S. Aymé, ??tat de la R&D dans les maladies rares, 10??ans apr??s le r??glement europ??en du m??dicament orphelin, La Presse M??dicale, vol.39, issue.5, 2010.
DOI : 10.1016/j.lpm.2010.02.001

J. Breitkreutz, European perspectives on pediatric formulations, Clinical Therapeutics, vol.30, issue.11, pp.2146-2154, 2008.
DOI : 10.1016/j.clinthera.2008.11.016

B. Buckley, Clinical trials of orphan medicines, The Lancet, vol.371, issue.9629, pp.2051-2055, 2008.
DOI : 10.1016/S0140-6736(08)60876-4

F. Butlen-ducuing, European Medicines Agency support mechanisms fostering orphan drug development, Drug News Perspect, vol.23, issue.1, 2010.

C. Concé and M. C. , Le médicament orphelin: un cadre juridique incitatif, Médecine & Droit, pp.176-184, 2006.

K. R. Grans-brangs and P. V. Plourde, The evolution of legislation to regulate pediatric clinical trials: Present and continuing challenges???, Advanced Drug Delivery Reviews, vol.58, issue.1, pp.106-115, 2006.
DOI : 10.1016/j.addr.2005.12.005

T. Gross, Challenges and practicalities of obtaining parental consent and child assent in paediatric trials, Regulatory Rapporteur ?, vol.7, p.6, 2010.

H. E. Heemstra, Orphan drug development across Europe: bottlenecks and opportunities, Drug Discovery Today, vol.13, issue.15-16, pp.670-676, 2008.
DOI : 10.1016/j.drudis.2008.05.001

H. E. Heemstra, Predictors of orphan drug approval in the European Union, European Journal of Clinical Pharmacology, vol.16, issue.5, pp.545-552, 2008.
DOI : 10.1007/s00228-007-0454-6

M. Braun and M. , Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years, Nature Reviews Drug Discovery, vol.354, pp.519-522, 2010.
DOI : 10.1038/nrd3160

G. Permanand, E. Mossialos, and M. Mckee, The EU's new paediatric medicines legislation: serving children's needs?, Archives of Disease in Childhood, vol.92, issue.9, pp.808-811, 2007.
DOI : 10.1136/adc.2006.105692

K. Rose, Ethical, Regulatory and Scientific Challenges in Paediatric Drug Development, Pharmaceutical Medicine, vol.49, issue.7, pp.221-234, 2008.
DOI : 10.1007/BF03256707

V. Sharma, EU Paediatric Regulation delaying new drugs, says TOPRA survey, RAJ Pharma, vol.22, issue.09, 2009.

Y. Sinha and N. E. Cranswick, How to use medicines in children: Principles of paediatric clinical pharmacology, Journal of Paediatrics and Child Health, vol.104, issue.3, pp.107-111, 2007.
DOI : 10.1185/146300903774115775

G. Vassal, Will children with cancer benefit from the new European Paediatric Medicines Regulation? European Journal of Cancer, pp.1535-1546, 2009.

R. Watson, Drugs industry urged to develop medicines for children, BMJ, vol.324, issue.7337, p.563, 2002.
DOI : 10.1136/bmj.324.7337.563/a

O. Wellman-labadie and Y. Zhou, The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?, Health Policy, vol.95, issue.2-3, pp.216-218, 2010.
DOI : 10.1016/j.healthpol.2009.12.001

?. Guideline, EMA et textes de loi Committee for Medicinal Products for Human Use (CHMP) Reflection Paper: Formulations of Choice for the Paediatric Population, 2005.

A. European-medicines, EMEA Public Statement on Fee Reduction for Designated Orphan Medicinal Products, 2009.

A. European-medicines, European Medicines Agency Guidance for Companies requesting Scientific Advice and Protocol Assistance. EMEA-H-4260-01-Rev, p.5, 2010.

A. European-medicines, Report to the European Commission ? Companies and products that have benefited from any of the rewards and incentives in the paediatric regulation and companies that have failed to comply with any of the obligations in this regulation covering the years, 2007.

A. European-medicines, Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population, 2005.

A. European-medicines, European Medicines Agency Guidance for Companies requesting Scientific Advice and Protocol Assistance. (EMEA-H-4260-01-Rev.6), p.5, 2010.

A. European-medicines, The Network of Paediatric Networks at the EMEA. Implementing Strategy, 2007.

A. European-medicines, Report on first workshop on a European Paediatric Research Network, 2009.

A. European-medicines, Report on second workshop of the European Paediatric Research Network (EnprEMA), 16, p.5, 2010.

A. European-medicines, Orphan medicines in number: The success of ten years of orphan legislation, p.5, 2010.

A. European-medicines, Paediatric Committee (EMA/PDCO) Meeting highlights from the Paediatric Commitee, pp.14-16451774, 2010.

D. Adrès-trelles and F. , The Paediatric Committee (PDCO) and the Paediatric Investigation Plan (PIP) What is relevant for Rare Diseases? The regulation on paediatric medicines to stimulate useful research on medicines for children is already in its 3 rd year. Présenté le 14 mai 2010 lors de la 5ème conférence Européenne sur les maladies rares, 2010.

C. Edfjäll, E. Ema-conference-10-yrs-of, /. W. Omp-regulation, and E. Pdf, Pharmaceutical Industry Perspective Présenté au cours de la conférence tenue par l'EMA à l'occasion des 10 ans de la Réglementation portant sur les médicaments orphelins (les 3 et 4 mai 2010) http://www.emea.europa.eu/docs/en_GB/document_library/Presentation Collaboration and exchange of information between the COMP and the Paediatric Committee Présenté au cours de la conférence tenue par l'EMA à l'occasion des 10 ans de la Réglementation portant sur les médicaments orphelins, WC500090763.pdf Fürst-Ladani S. Challenges for Manufacturers of Orphan Medicinal Products and PIP Case Studies, pp.8-1003, 2010.

B. C. Lehmann and . Studies, Experience from the Regulators, pp.30-31, 2008.

L. Mathis, Unapproved Drug Workshop Pediatric Studies Présenté le 9 janvier Consulté sur http://www.fda.gov/downloads/AboutFDA, 2007.

R. K. Eu, Paediatric Regulation: Strategic Challenges and Opportunities for the Pharmaceutical Industry, IFAAPEU_Paediatric_Regulation_Strategic_Challenges_and_Opportunities_for_the_Pharmaceutical_Industry, pp.114-156, 2007.

K. Rose, Impact of the EU Paediatric Regulation: Assessing the first 3 years, Présenté au 22ème EuroMeeting Monaco, 2010.

A. Tummavuori and . Eu, Paediatric Regulation: How to prepare PIP/waiver dossier? Présenté à l'EMEA SME Workshop, 2009.

K. Westermark, 10 years of experience with Orphan drugs and challenges for the future Présenté le 14 mai 2010 lors de la 5ème conférence Européenne sur les maladies rares, Krakow (13-15 mai 2010) http://www.rare-diseases, 2010.

D. Borfitz, Orphan Drug Research Suddenly in Vogue, 2010.

F. , D. De-jesse, and L. Goodman, FDA's chief scientist and deputy commissioner for science and public health) before Senate HELP Committee, Treating Rare and Neglected Pediatric Diseases: Promoting the Development of New Treatments and Cures, 2010.

. Healthnewsdigest and . Com, Orphan Drugs to Create Paradigm Shift in the Pharmaceuticals Industry Article du 6, consulté le 15, 2010.

K. Hoppu, A Summary of the EU Paediatric Initiatives. WHO Expert Consultation on Essential Medicines for Children, 9 ? 13, 2007.

H. C. Sachs, Pediatric Drug Development : The FDA Experience, CDER Forum for International Drug Regulatory Authorities, 2008.

C. Vanchieri, S. Butler, A. Knutsen, and A. , Addressing the Barriers to Pediatric Drug Development: Workshop Summary (téléchargé sur http, 2008.